KURA ONCOLOGY INC. -

NetDania - New 12 months High: KURA ONCOLOGY INC. - COMMON STOCK

04 Jan 2024 11:14:50 By NetDania Notify

NetDania - New 12 months High: KURA ONCOLOGY INC. - COMMON STOCK

02 Jan 2024 10:09:11 By NetDania Notify

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

08 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

28 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Third Quarter 2023 Financial Results

02 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

02 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Three Upcoming Investor Conferences

30 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Report Third Quarter 2023 Financial Results

26 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

19 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC

17 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

04 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer

28 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Cantor Global Healthcare Conference 2023

19 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

14 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Second Quarter 2023 Financial Results

03 Aug 2023 16:05:03 By Nasdaq GlobeNewswire

Kura Oncology to Report Second Quarter 2023 Financial Results

27 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

14 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants

13 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

11 Jun 2023 03:45:00 By Nasdaq GlobeNewswire

Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress

30 May 2023 07:30:00 By Nasdaq GlobeNewswire